Joseph J. Lynch - Concepedia

Author

Joseph J. Lynch

Also Known As

Elizabeth Marsh Lyle, J J Lynch, J Lynch, J. J. JUN. LYNCH, J. J. LYNCH, J. J. Lynch, J. Lynch, J.J. Lynch, J.J. Lynch Jr., John J. Lynch

213

Publications

6.7K

Citations

H-Index

131

Concepts

All Affiliations

United States Military Academy University of Michigan

About

Joseph J. Lynch is an author at United States Military Academy specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	80	3.4K
2	Natural Sciences	22	26	1.5K
3	Health Sciences	6	6	191
4	Engineering	1	1	52
5	Language Studies	1	1	13

Joseph J. Lynch

143

Publications

6.3K

Citations

H-Index

Page 1

	Year	Citations
Increased endothelial albumin permeability mediated by protein kinase C activation. Joseph J. Lynch, Thomas J. Ferro, F. A. Blumenstock, Journal of Clinical Investigation 125I-albumin PermeabilityCell AdhesionCellular PhysiologyInflammationAngiogenesis	1990	270
Design and Synthesis of 8-Hydroxy-[1,6]Naphthyridines as Novel Inhibitors of HIV-1 Integrase in Vitro and in Infected Cells Linghang Zhuang, John Wai, Mark W. Embrey, Journal of Medicinal Chemistry Hiv-1 IntegraseBiochemistryMedicineImmunologyAntiviral Drug Development	2003	266
Cardiac Electrophysiological Actions of the Histamine H<sub>1</sub>-Receptor Antagonists Astemizole and Terfenadine Compared With Chlorpheniramine and Pyrilamine Joseph J. Salata, Nancy K. Jurkiewicz, Audrey A. Wallace, Circulation Research	1995	211
Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp Melissa S. Egbertson, C. T.‐C. CHANG, Mark E. Duggan, Journal of Medicinal Chemistry	1994	178
Biological Profile of L-745,870, a Selective Antagonist with High Affinity for the Dopamine D4 Receptor Smita S. Patel, Stephen B. Freedman, Kerry L. Chapman, Journal of Pharmacology and Experimental Therapeutics	1997	165
Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Gary R. Sitko, Denise Ramjit, Inez I. Stabilito, Circulation	1992	131
The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation Erich Wettwer, Torsten Christ, Sebastian Endig, Cardiovascular Research	2013	125
Metabolism-Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines Christopher S. Burgey, Kyle A. Robinson, Terry A. Lyle, Journal of Medicinal Chemistry Pharmaceutical ScienceOral BioavailabilityPharmacotherapyPharmaceutical ChemistryMolecular Pharmacology	2003	120
Use-Dependent Effects of the Class III Antiarrhythmic Agent NE-10064 (Azimilide) on Cardiac Repolarization Bernard Fermini, Nancy K. Jurkiewicz, Brian Jow, Journal of Cardiovascular Pharmacology	1995	113
Design and Synthesis of a Series of Potent and Orally Bioavailable Noncovalent Thrombin Inhibitors That Utilize Nonbasic Groups in the P1 Position Thomas J. Tucker, Stephen F. Brady, William C. Lumma, Journal of Medicinal Chemistry Pharmaceutical ScienceBioorganic ChemistryPharmacotherapyUtilize Nonbasic GroupsChemical Biology	1998	105

Page 1